Carborane Conjugates with Ibuprofen, Fenoprofen and Flurbiprofen: Synthesis, Characterization, COX Inhibition Potential and In Vitro Activity.

carboranes drug conjugates fenoprofen flurbiprofen ibuprofen

Journal

ChemMedChem
ISSN: 1860-7187
Titre abrégé: ChemMedChem
Pays: Germany
ID NLM: 101259013

Informations de publication

Date de publication:
06 Jun 2024
Historique:
revised: 03 06 2024
received: 07 01 2024
accepted: 05 06 2024
medline: 7 6 2024
pubmed: 7 6 2024
entrez: 6 6 2024
Statut: aheadofprint

Résumé

The most effective anticancer drugs currently entail substantial and formidable side effects, and resistance of tumors to chemotherapeutic agents is a further challenge. Thus, the search for new anticancer drugs as well as novel therapeutic methods is still extremely important. Non-steroidal anti-inflammatory drugs (NSAIDs) can inhibit COX (cyclooxygenase), overexpressed in some tumors. Carboranes are emerging as promising pharmacophores. We have therefore combined both moieties in a single molecule to design drugs with a dual mode of action and enhanced effectiveness. The NSAIDs ibuprofen, flurbiprofen, and fenoprofen were connected with 1,2-dicarba-closo-dodecaborane(12) via methylene, ethylene or propylene spacers. Three sets of carborane-NSAID conjugates were synthesized and analyzed through multinuclear (1H, 11B, and 13C) NMR spectroscopy. Conjugates with methylene spacers exhibited the most potent COX inhibition potential, particularly conjugates with flurbiprofen and fenoprofen, displaying higher selectivity towards COX-1. Furthermore, conjugates with methylene and ethylene spacers were more efficient in suppressing the growth of human cancer cell lines than their propylene counterparts. The carborane-flurbiprofen conjugate with an ethylene spacer was the most efficient and selective toward the COX-2-negative cell line HCT116. Its mode of action was basically cytostatic with minor contribution of apoptotic cell death and dominance of cells trapped in the division process.

Identifiants

pubmed: 38844420
doi: 10.1002/cmdc.202400018
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e202400018

Informations de copyright

© 2024 Wiley‐VCH GmbH.

Auteurs

Sonam Sonam (S)

University of Applied Sciences Merseburg Faculty of Engineering and Sciences, Department of Engineering and Sciences, GERMANY.

Sanja Jelača (S)

University of Belgrade Institute for Biological Research Sinisa Stankovic, Department of Immunology, SERBIA.

Markus Laube (M)

Helmholtz Centre Dresden-Rossendorf Institute of Radiopharmaceutical Cancer Research, Department of Radiopharmaceutical and Chemical Biology, GERMANY.

Jonas Schädlich (J)

Helmholtz Centre Dresden-Rossendorf Institute of Radiopharmaceutical Cancer Research, Department of Radiopharmaceutical and Chemical Biology, GERMANY.

Jens Pietzsch (J)

Helmholtz Centre Dresden-Rossendorf Institute of Radiopharmaceutical Cancer Research, Department of Radiopharmaceutical and Chemical Biology, GERMANY.

Danijela Maksimović-Ivanić (D)

University of Belgrade Institute for Biological Research Sinisa Stankovic, Department of Immunology, SERBIA.

Sanja Mijatović (S)

University of Belgrade Institute for Biological Research Sinisa Stankovic, Department of Immunology, SERBIA.

Goran N Kaluđerović (GN)

University of Applied Sciences Merseburg, Deparment of Engineering and Natural Sciences, Eberhard-Leibnitz-Strasse 2, 06217, Merseburg, GERMANY.

Evamarie Hey-Hawkins (E)

Leipzig University, Institute of Bioanalytical Chemistry, GERMANY.

Classifications MeSH